Cambridge Epigenetix and NuGEN begin collaboration

Cambridge Epigenetix, a spin-out from the University of Cambridge, has entered into a partnership to integrate its CEGX TrueMethyl technology with library preparation kits from NuGEN Technologies, a privately-held US genetic analysis company.

Cambridge Epigenetix says the deal will enable it to focus on its epigenetic biomarker discovery programs, in-house and through partnerships.

Jason Mellad, the company’s chief executive, said: “This partnership will enable both Cambridge Epigenetix and NuGEN to leverage our strengths to facilitate advances in the epigenetics field.”